S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
OncLive® On Air
00:00
OPTIC Results Favoring 45→15 Strategy
Elias Jabbour explains OPTIC showed best efficacy/safety balance with 45 mg reduced to 15 mg upon response, changing ponatinib labeling.
Play episode from 06:27
Transcript
